Filing summary
Entity note: The request identifies Gyre Therapeutics, Inc., but the supplied Form 10-Q is for Catalyst Biosciences, Inc. This summary reflects the filing provided, not a Gyre filing.
Business context and reporting period
This unaudited 10-Q covers the three months ended March 31, 2021, with balance-sheet comparisons to December 31, 2020. Catalyst is a clinical-stage biopharmaceutical company developing engineered protease candidates for complement and coagulation disorders. It had no products approved for sale and generated no product-sales revenue.
Key programs included MarzAA, in a registrational Phase 3 trial for episodic bleeding in hemophilia patients with inhibitors; CB 4332, in preclinical development for CFI deficiency; CB 2782-PEG, a dry-AMD candidate licensed to Biogen; and DalcA, which had completed a Phase 2b study.
Financial performance and liquidity
Amounts below are in millions of dollars except per-share data. The filing’s financial statements are unaudited.
| Metric | Q1 2021 | Q1 2020 |
|---|---|---|
| License and collaboration revenue | $1.47 | $16.37 |
| Operating expenses | $23.91 | $21.43 |
| Research and development expense | $17.01 | $13.26 |
| General and administrative expense | $5.41 | $3.69 |
| Net loss | $(22.44) | $(4.05) |
| Net loss per share, basic and diluted | $(0.79) | $(0.28) |
| Cash used in operating activities | $(24.36) | $(4.79) |
- At March 31, cash and cash equivalents were $83.04 million, short-term investments were $23.96 million, and total cash, cash equivalents and investments were $107.0 million.
- Total assets were $119.08 million; total liabilities were $14.99 million. The filing reports no borrowings; liabilities included operating lease obligations of $1.48 million, of which $0.68 million was current.
- Q1 financing provided $49.46 million, principally from a public offering. Investing activities provided $27.58 million, mainly from investment maturities.
- Accumulated deficit was $337.20 million. No operating margin is stated; the company reported an operating loss of $22.44 million.
Material changes versus the prior comparable period
- Revenue fell 91% year over year, primarily because Q1 2020 included recognition of Biogen’s $15.0 million upfront license payment. Q1 2021 revenue was primarily reimbursable collaboration costs.
- R&D expense increased 28%, mainly from higher preclinical spending and personnel costs. General and administrative expense increased 47%, primarily due to personnel and professional-services costs.
- Net loss increased by $18.39 million. The prior-year quarter included $1.02 million of interest and other income; Q1 2021 reported approximately zero net interest and other income.
- Operating cash use increased to $24.36 million from $4.79 million. The year-over-year comparison was also affected by changes in receivables and deferred revenue.
- The company sold 9.185 million shares at $5.75 per share in Q1, raising approximately $49.3 million net. Shares outstanding increased to 31.33 million from 22.10 million at year-end 2020.
Outlook, risks and notable items
- Management expected existing cash, cash equivalents and investments to fund requirements for at least 12 months from the filing date, while warning that estimates depend on assumptions and funding may be needed. The company expected continuing losses and increasing R&D spending.
- COVID-19 had delayed enrollment in the MAA-304 and MAA-202 MarzAA trials. The filing cites potential further enrollment, manufacturing, supply-chain, clinical-site and regulatory delays.
- Management planned to submit the first MAA-304 Data and Safety Monitoring Board report and report interim MAA-202 pharmacokinetic data in 2021. It intended to begin an observational CFI-deficiency study in mid-2021 and described a potential CB 4332 Phase 1/2 study in 2022. These are plans, not guaranteed outcomes.
- Biogen’s agreement offers up to $340 million in development and sales milestones plus royalties, but the timing and receipt of future payments are uncertain. The filing reports up to $19.5 million of potential DalcA milestones payable to ISU Abxis and contingent Pfizer payments of up to $17.5 million tied to specified milestones.
- Firm AGC manufacturing work orders for MarzAA and DalcA totaled $17.1 million, with $4.5 million of payment obligations remaining at quarter-end. The filing also disclosed a new laboratory and office lease beginning May 1, 2021.
- Management reported effective disclosure controls and no material change in internal control over financial reporting. The company reported no material legal proceedings and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Catalyst Biosciences, Inc., not Gyre Therapeutics, Inc.
- Track enrollment and timelines for the MarzAA trials, including the effects of COVID-19 and competition for eligible patients.
- Assess quarterly operating cash burn against the $107.0 million of cash, cash equivalents and investments, and monitor whether additional financing is required.
- Review the impact of equity issuance and potential future dilution, as well as the terms and availability of any further financing.
- Verify progress toward planned CB 4332 studies and the timing and probability of Biogen milestones or royalties; these payments are contingent.
- Monitor manufacturing commitments, remaining AGC obligations, and risks to clinical supply and trial schedules.